Saturday 17 October 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.

19.67 0.22 +1.13%

Follow TAK

Alert me

Market cap: $61.9B
P/E: 29.6×
Fwd P/E: —
Dividend yield: 1.57%
F-score: 4/9
Altman Z: 1.03
Beneish M: −2.65
Dividend safety: 25/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 13.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	17	2	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 61,900.00

Revenue 29,991.30

Net Income 2,884.69

Free Cash Flow 7,420.86

Net Debt 27,798.03

Current Ratio 1.14

Debt/Equity 0.65

P/E ratio 29.60

Fwd P/E —

P/S ratio 2.07

P/B ratio 1.31

Past 5Y EPS Growth —

This Y EPS Growth 1.82%

Next Y EPS Growth 60.25%

Next Y revenue growth —

Next 5Y EPS Growth 25.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 52.76%

10-year low 10-year high

P/S against its own 10 years 71.40%

10-year low 10-year high

P/B against its own 10 years 61.52%

10-year low 10-year high

EV/Sales against its own 10 years 77.81%

10-year low 10-year high

EV/FCF against its own 10 years 69.04%

10-year low 10-year high

Dividends

Payout Ratio 0.46

Annual Dividend Rate 0.31

Annual Dividend Yield 1.57%

	total	individual payouts
2026	0.31	0.31
2025	0.66	0.34 0.32
2024	0.62	0.29 0.33
2023	0.63	0.31 0.32
2022	0.66	0.33 0.33
2021	0.80	0.41 0.40
2020	0.85	0.42 0.43
2019	1.25	0.42 0.42 0.41
2018	1.40	0.30 0.41 0.30 0.40
2017	1.46	0.36 0.40 0.31 0.40
2016	1.44	0.32 0.44 0.29 0.39

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3,263	2,677	4,204	3,324
Receivables	4,814	4,787	5,784	6,024
Inventory	8,348	8,035	9,218	9,118
Other	1,230	1,142	1,192	1,382
	17,654	16,640	20,397	19,847

	2024	2025	2026	Q'26
Payables	3,778	3,139	3,243	2,815
ST’ Debt	2,534	3,623	3,380	3,276
Other	8,890	8,900	11,423	10,583
	15,960	16,543	18,692	17,417

Compound Annual Growth %

	10y	5y	3y
Sales	7.08%	(0.21%)	(0.07%)
Cash Flow	41.64%	(6.27%)	(1.68%)
Earnings	0.00%	0.00%	0.00%
Book Value	11.38%	0.15%	1.41%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	7,685	—	—	—	—
’26	7,636	—	—	—	29,738
’25	7,731	—	—	—	30,238
’24	7,728	7,197	7,556	6,939	29,420
’23	7,488	7,217	7,786	7,313	29,803
’22	8,641	7,688	7,931	7,504	31,764
’21	7,457	7,416	8,033	7,153	30,059

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	804	—	—	—	—
’26	1,486	2,550	6,285	—	6,873
’25	1,090	1,934	5,511	—	6,977
’24	675	1,335	967	1,966	4,943
’23	649	1,549	2,655	2,378	7,231
’22	1,518	2,122	2,938	3,417	9,996
’21	1,357	2,328	2,171	3,647	9,503

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	161	—	—	—	—
’26	1,013	2,198	4,050	—	4,179
’25	208	1,486	3,618	—	4,472
’24	(1,291)	1,017	477	1,481	1,685
’23	(109)	1,306	2,309	(958)	2,549
’22	1,134	1,729	2,538	2,955	8,356
’21	980	2,306	1,785	2,645	7,717

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.22	—	—	—	—
’26	0.27	—	—	—	(0.32)
’25	0.19	—	—	—	0.22
’24	0.21	(0.11)	0.23	(0.02)	0.30
’23	0.26	0.14	0.29	0.08	0.75
’22	0.58	0.13	0.17	(0.23)	0.65
’21	0.25	0.01	0.28	0.59	1.13

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	20.20	15.50	16.10	12.43	13.17	12.28	13.19	12.58	12.80	14.84	Analyst estimates 2027–2029 Powerpack
	High	29.15	31.29	21.61	20.42	19.97	15.66	17.15	15.08	15.78	19.89
People
People	Employees	27,230	27,230	49,578	47,495	47,000	47,347	49,095	49,281	47,455	47,000
	Revenue/emp, $m	0.59	0.59	0.38	0.64	0.64	0.67	0.61	0.60	0.64	0.63
Income, $m
Income, $m	Revenue	16,108	15,935	18,875	30,279	30,059	31,764	29,803	29,420	30,238	29,738
	Gross margin, %	67.74	71.99	68.54	66.89	131.09	68.99	69.11	66.54	65.51	65.12
	EBT	1,333	1,955	854	(559)	3,443	2,693	2,776	364	1,156	(940)
	EBT margin, %	8.28	12.27	4.52	(1.85)	11.45	8.48	9.31	1.24	3.82	(3.16)
	Net income	1,074	1,680	981	407	3,536	2,048	2,346	995	714	(1,004)
	Depreciation	2,072	1,639	2,452	5,370	5,261	5,190	4,917	5,023	5,025	4,759
Per share, $
Per share, $	Revenue	10.31	10.20	9.82	9.72	9.62	10.16	9.60	9.40	9.58	9.44
	Earnings	0.68	1.08	0.51	0.13	1.14	0.66	0.76	0.31	0.22	(0.32)
	Cash flow	1.56	2.18	1.54	1.98	3.04	3.20	2.33	1.58	2.21	2.18
	Capex	(0.65)	(0.72)	(0.39)	(0.61)	(0.57)	(0.52)	(1.51)	(1.04)	(0.79)	(0.86)
	Free cash flow	0.91	1.46	1.15	1.37	2.47	2.67	0.82	0.54	1.42	1.33
	Book value	11.60	11.63	24.17	13.97	15.58	16.18	15.15	16.04	14.50	15.57
	Shares, m	1,562	1,562	1,923	3,114	3,124	3,127	3,104	3,129	3,158	3,150
Valuation, ×
Valuation, ×	P/E	0.00	65.94	9.76	116.50	16.02	21.80	21.40	42.87	49.75	27.45
	P/S	2.38	2.40	1.92	1.56	1.90	1.41	1.72	1.45	1.59	1.94
	P/B	2.13	2.02	1.76	1.09	1.17	0.89	1.09	0.85	0.95	1.17
	EV/Sales	2.51	2.79	2.29	2.91	3.03	2.38	2.67	2.48	2.55	2.83
	EV/FCF	4.21	4.63	5.44	20.62	11.82	9.06	31.18	43.28	11.06	7.77
Cash, $m
Cash, $m	Operating cash flow	2,431	3,401	2,956	6,162	9,503	9,996	7,231	4,943	6,977	6,873
	Capex	(1,014)	(1,128)	(751)	(1,887)	(1,786)	(1,640)	(4,682)	(3,258)	(2,505)	(2,694)
	Free cash flow	1,417	2,273	2,206	4,275	7,717	8,356	2,549	1,685	4,472	4,179
Balance, $m
Balance, $m	Working capital	(980)	3,072	4,858	2,701	8,833	3,986	(621)	1,694	97	1,706
	Total debt	10,647	8,871	51,759	46,858	43,572	38,674	32,429	33,422	29,801	32,220
	Net debt	7,149	5,494	45,230	40,847	34,146	30,887	28,332	30,159	27,124	28,016
	Shareholders’ equity	18,125	18,157	46,472	43,493	48,665	50,583	47,025	50,191	45,777	49,042
Returns, %
Returns, %	ROA	2.96	4.34	1.21	0.34	2.95	1.72	2.13	0.96	0.72	(1.02)
	ROIC	3.58	5.75	1.26	0.68	17.72	3.15	3.01	1.15	1.94	0.03
	ROE	6.14	9.27	3.04	0.90	7.67	4.13	4.81	2.05	1.48	(2.12)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$61.9B	29.6×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	−95.56% (below 0%: shrinking)	66.66%	16.51%
TEVA Teva Pharmaceutical Industries Ltd.	$47.9B	65.9×	30.7×	−0.81% (below 0%: shrinking)	n/m	+121.43% (above 0%: growing)	51.98%	(2.03%)	Compare
HLN Haleon PLC Sponsored ADR	$43.7B	22.6×	17.6×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%	Compare
ZTS Zoetis Inc.	$32.4B	13.0×	12.3×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
Median of peers	$22.1B	20.9×	27.4×	−0.28%	+22.59%	+39.63%	60.61%	11.89%

All 86 Drug Manufacturers Specialty & Generic stocks →

Takeda Pharmaceutical Co. (TAK) key facts

Concern: Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
Takeda Pharmaceutical Co. (TAK) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, TAK traded at $19.67, a market capitalization of $61.9 billion.
Takeda Pharmaceutical Co. pays an annual dividend of $0.31 per share, a yield of 1.57%, with a payout ratio of 46.5%.
Return on equity was −2.12% and debt-to-equity 0.65.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.03 (distress zone) for fiscal 2026.